SCHEMBL17809691

SCHEMBL17809691

Cc1ccc(-c2cn(C)nc2C(F)(F)F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.49
CYP3A4 P08684 1/20 0.49
PRMT5 O14744 1/20 0.46
WDR77 Q9BQA1 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
BRD4 O60885 4/20 0.44
ALDH1A1 P00352 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
CREBBP Q92793 3/20 0.42
ENPP1 P22413 1/20 0.42
MAPK13 O15264 1/20 0.40
CSNK1D P48730 1/20 0.40
CSNK1E P49674 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17437098 0.85 POLB (0.51) CYP2C19CYP3A4PRMT5WDR77CYP1A2
SCHEMBL21051463 0.85 PRMT5 (0.45) CYP2C19CYP3A4PRMT5WDR77CYP1A2
SCHEMBL7039667 0.84 POLB (0.49) CYP2C19CYP3A4PRMT5WDR77CYP1A2
SCHEMBL17806579 0.82 PRMT5 (0.44) CYP2C19CYP3A4PRMT5WDR77CYP1A2
SCHEMBL17809821 0.81 ALDH1A1 (0.49) CYP2C19CYP3A4PRMT5WDR77CYP1A2
SCHEMBL12859287 0.78 MAPK13 (0.42) PRMT5WDR77BRD4ALDH1A1L3MBTL1
SCHEMBL21051442 0.78 BRD4 (0.49) CYP2C19CYP3A4PRMT5WDR77CYP1A2
SCHEMBL17809689 0.78 CYP2C19 (0.45) CYP2C19CYP3A4CYP1A2CYP2C9HTT
SCHEMBL17799563 0.76 PRMT5 (0.50) CYP2C19CYP3A4PRMT5WDR77CYP1A2
SCHEMBL30553371 0.76 PRMT5 (0.42) CYP2C19CYP3A4PRMT5WDR77CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3224258-B1 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH INC (US) 2019-08-14 EP disclosed
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-23 US disclosed
US-9763922-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2017-09-19 US disclosed
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 CYP2C19 3069/4885CYP3A4 3799/4885PRMT5 282/4885
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 CYP2C19 3069/4885CYP3A4 3799/4885PRMT5 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.